Bicara Therapeutics (BCAX) Competitors $11.65 +0.86 (+7.97%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$11.78 +0.14 (+1.16%) As of 07/17/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BCAX vs. INDV, RXRX, DNLI, BEAM, KNSA, BLTE, CNTA, VCEL, IRON, and HRMYShould you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include Indivior (INDV), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Kiniksa Pharmaceuticals International (KNSA), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Vericel (VCEL), Disc Medicine (IRON), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Bicara Therapeutics vs. Its Competitors Indivior Recursion Pharmaceuticals Denali Therapeutics Beam Therapeutics Kiniksa Pharmaceuticals International Belite Bio Centessa Pharmaceuticals Vericel Disc Medicine Harmony Biosciences Bicara Therapeutics (NASDAQ:BCAX) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings. Do insiders & institutionals have more ownership in BCAX or INDV? 60.3% of Indivior shares are held by institutional investors. 15.5% of Bicara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher earnings and valuation, BCAX or INDV? Indivior has higher revenue and earnings than Bicara Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/A-$68MN/AN/AIndivior$1.19BN/A$2M-$0.31-52.13 Do analysts recommend BCAX or INDV? Bicara Therapeutics presently has a consensus target price of $31.86, suggesting a potential upside of 173.46%. Indivior has a consensus target price of $17.00, suggesting a potential upside of 5.20%. Given Bicara Therapeutics' higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than Indivior.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Indivior 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Is BCAX or INDV more profitable? Bicara Therapeutics has a net margin of 0.00% compared to Indivior's net margin of -4.02%. Bicara Therapeutics' return on equity of 0.00% beat Indivior's return on equity.Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A N/A N/A Indivior -4.02%-97.29%15.74% Does the media prefer BCAX or INDV? In the previous week, Bicara Therapeutics had 3 more articles in the media than Indivior. MarketBeat recorded 3 mentions for Bicara Therapeutics and 0 mentions for Indivior. Indivior's average media sentiment score of 1.87 beat Bicara Therapeutics' score of 0.85 indicating that Indivior is being referred to more favorably in the news media. Company Overall Sentiment Bicara Therapeutics Positive Indivior Very Positive SummaryBicara Therapeutics and Indivior tied by winning 6 of the 12 factors compared between the two stocks. Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition Export to ExcelMetricBicara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$588.45M$2.94B$5.57B$9.34BDividend YieldN/A2.45%3.80%4.06%P/E RatioN/A20.2928.1019.86Price / SalesN/A302.32441.4199.96Price / CashN/A43.1635.8457.94Price / Book1.297.838.265.67Net Income-$68M-$55.11M$3.24B$257.80M7 Day Performance19.98%3.21%1.48%1.87%1 Month Performance23.54%12.86%8.07%10.92%1 Year PerformanceN/A5.06%30.29%18.51% Bicara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara Therapeutics1.7912 of 5 stars$11.65+8.0%$31.86+173.5%N/A$588.45MN/A0.0032News CoverageINDVIndivior1.4783 of 5 stars$15.62+1.0%$17.00+8.8%+50.0%$2.15B$1.17B-50.391,051Upcoming EarningsRXRXRecursion Pharmaceuticals1.8505 of 5 stars$5.28flat$7.00+32.6%-33.9%$2.15B$59.82M-2.98400DNLIDenali Therapeutics4.6241 of 5 stars$14.69+1.2%$33.71+129.5%-36.9%$2.13B$330.53M-5.50430BEAMBeam Therapeutics2.0918 of 5 stars$21.17+0.0%$48.75+130.3%-24.1%$2.13B$63.52M-4.59510KNSAKiniksa Pharmaceuticals International3.3473 of 5 stars$28.80+2.5%$39.33+36.6%+34.7%$2.10B$423.24M-115.20220Positive NewsUpcoming EarningsInsider TradeBLTEBelite Bio2.015 of 5 stars$63.58+0.6%$96.67+52.0%+26.6%$2.02BN/A-46.7510High Trading VolumeCNTACentessa Pharmaceuticals3.4102 of 5 stars$15.13+4.9%$27.89+84.3%+67.6%$2.02B$15M-8.36200Positive NewsHigh Trading VolumeVCELVericel3.6794 of 5 stars$39.82-0.3%$61.14+53.5%-29.9%$2.00B$238.54M1,327.78300News CoveragePositive NewsIRONDisc Medicine3.1234 of 5 stars$57.74+1.5%$96.70+67.5%+21.4%$2.00BN/A-14.7330HRMYHarmony Biosciences4.8046 of 5 stars$34.71+2.1%$51.33+47.9%+10.1%$1.99B$714.73M13.25200Positive News Related Companies and Tools Related Companies INDV Competitors RXRX Competitors DNLI Competitors BEAM Competitors KNSA Competitors BLTE Competitors CNTA Competitors VCEL Competitors IRON Competitors HRMY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
